AAPL   393.54 (+2.57%)
MSFT   214.52 (+0.40%)
FB   249.57 (+1.84%)
AMZN   3,286.36 (+2.70%)
NVDA   431.41 (+2.92%)
CGC   17.45 (+0.11%)
BABA   264.91 (+1.49%)
MU   51.86 (+2.27%)
GE   6.74 (+0.75%)
TSLA   1,751.56 (+13.40%)
AMD   58.05 (+3.88%)
T   29.86 (-0.90%)
AAPL   393.54 (+2.57%)
MSFT   214.52 (+0.40%)
FB   249.57 (+1.84%)
AMZN   3,286.36 (+2.70%)
NVDA   431.41 (+2.92%)
CGC   17.45 (+0.11%)
BABA   264.91 (+1.49%)
MU   51.86 (+2.27%)
GE   6.74 (+0.75%)
TSLA   1,751.56 (+13.40%)
AMD   58.05 (+3.88%)
T   29.86 (-0.90%)
AAPL   393.54 (+2.57%)
MSFT   214.52 (+0.40%)
FB   249.57 (+1.84%)
AMZN   3,286.36 (+2.70%)
NVDA   431.41 (+2.92%)
CGC   17.45 (+0.11%)
BABA   264.91 (+1.49%)
MU   51.86 (+2.27%)
GE   6.74 (+0.75%)
TSLA   1,751.56 (+13.40%)
AMD   58.05 (+3.88%)
T   29.86 (-0.90%)
AAPL   393.54 (+2.57%)
MSFT   214.52 (+0.40%)
FB   249.57 (+1.84%)
AMZN   3,286.36 (+2.70%)
NVDA   431.41 (+2.92%)
CGC   17.45 (+0.11%)
BABA   264.91 (+1.49%)
MU   51.86 (+2.27%)
GE   6.74 (+0.75%)
TSLA   1,751.56 (+13.40%)
AMD   58.05 (+3.88%)
T   29.86 (-0.90%)
Log in

NASDAQ:LQDALiquidia Technologies Stock Price, Forecast & News

$7.38
-0.06 (-0.81 %)
(As of 07/13/2020 09:50 AM ET)
Add
Compare
Today's Range
$7.34
Now: $7.38
$7.52
50-Day Range
$7.30
MA: $8.84
$11.44
52-Week Range
$2.65
Now: $7.38
$12.10
Volume8,371 shs
Average Volume548,078 shs
Market Capitalization$209.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More
Liquidia Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LQDA
CUSIPN/A
CIKN/A
Phone919-328-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.07 million
Book Value$1.24 per share

Profitability

Net Income$-47,580,000.00

Miscellaneous

EmployeesN/A
Market Cap$209.37 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive LQDA News and Ratings via Email

Sign-up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.

Liquidia Technologies (NASDAQ:LQDA) Frequently Asked Questions

How has Liquidia Technologies' stock been impacted by COVID-19 (Coronavirus)?

Liquidia Technologies' stock was trading at $3.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LQDA shares have increased by 103.3% and is now trading at $7.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Liquidia Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Liquidia Technologies.

When is Liquidia Technologies' next earnings date?

Liquidia Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Liquidia Technologies.

How were Liquidia Technologies' earnings last quarter?

Liquidia Technologies Inc (NASDAQ:LQDA) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.01. View Liquidia Technologies' earnings history.

What price target have analysts set for LQDA?

3 brokerages have issued 12-month price objectives for Liquidia Technologies' stock. Their forecasts range from $24.00 to $40.00. On average, they expect Liquidia Technologies' stock price to reach $34.00 in the next year. This suggests a possible upside of 357.0% from the stock's current price. View analysts' price targets for Liquidia Technologies.

Has Liquidia Technologies been receiving favorable news coverage?

Media stories about LQDA stock have been trending very negative on Monday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Liquidia Technologies earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Liquidia Technologies.

Are investors shorting Liquidia Technologies?

Liquidia Technologies saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,420,000 shares, an increase of 43.3% from the June 15th total of 990,600 shares. Based on an average trading volume of 209,800 shares, the short-interest ratio is currently 6.8 days. Approximately 9.5% of the company's shares are sold short. View Liquidia Technologies' Current Options Chain.

Who are some of Liquidia Technologies' key competitors?

What other stocks do shareholders of Liquidia Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia Technologies investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Amarin (AMRN), Protalix Biotherapeutics (PLX), VBI Vaccines (VBIV), Vaxart (VXRT), Zynerba Pharmaceuticals (ZYNE), Anavex Life Sciences (AVXL) and Aytu Bioscience (AYTU).

Who are Liquidia Technologies' key executives?

Liquidia Technologies' management team includes the following people:
  • Mr. Neal F. Fowler, CEO & Director (Age 57)
  • Mr. Robert A. Lippe, Chief Operations Officer (Age 54)
  • Mr. William R. Kenan Jr., Co-Founder
  • Dr. Ginger Denison, Co-Founder
  • Mr. Timothy M. Albury, Interim Chief Financial Officer (Age 50)

When did Liquidia Technologies IPO?

(LQDA) raised $50 million in an IPO on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is Liquidia Technologies' stock symbol?

Liquidia Technologies trades on the NASDAQ under the ticker symbol "LQDA."

How do I buy shares of Liquidia Technologies?

Shares of LQDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Liquidia Technologies' stock price today?

One share of LQDA stock can currently be purchased for approximately $7.44.

How big of a company is Liquidia Technologies?

Liquidia Technologies has a market capitalization of $211.07 million and generates $8.07 million in revenue each year. The company earns $-47,580,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

What is Liquidia Technologies' official website?

The official website for Liquidia Technologies is www.liquidia.com.

How can I contact Liquidia Technologies?

Liquidia Technologies' mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company can be reached via phone at 919-328-4400 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.